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a b s t r a c t
Parasitic diseases caused by protozoarian agents are still relevant today more than ever. Recently, we
synthesized several polycondensed diazine derivatives by means 1,3-dipolar cycloaddition reactions. A
broad selection of these compounds were submitted to in vitro biological screening against Plasmodium
falciparum, Leishmania infantum, Trypanosoma brucei, and Trypanosoma cruzi, resulting active at micromo-
lar level. Induced Fit Docking/MM-GBSA studies were performed giving interesting indications about the
probable mechanism of action of the most active compounds
 2011 Elsevier Ltd. All rights reserved.
Parasitic diseases are the cause of signiﬁcant mortality and
morbidity worldwide. The WHO estimates that approximately
247 million people are infected with malaria annually, resulting
in approximately 1 million deaths. In addition, an estimated 1 bil-
lion people are affected by parasitic infections, such as leishmani-
asis, trypanosomiasis. The annual mortality associated with
parasitic infections, excluding malaria, is an estimated 500,000
deaths.1 The majority of the drugs used to treat these diseases is
old and has several limitations, including high cost, poor efﬁcacy,
toxicity.2 Moreover, the development of drug resistance makes ac-
tual the research of new molecules able to act as selective and
effective anti-parasitic chemotherapeutic agents.
Several azineor diazineheterocycles (pyridine, pyrazine, quinox-
alines), as well as their ring-fused bioisosteric analogs, have shown
marked activity inmany biological systems. A large number of com-
pounds incorporating these ring systems was found to posses anti-
microbial or anti-parasitic activities.3,4 Therefore we decided to
study polycondensed diazine systems, incorporating the quinoxa-
line moiety, for their potential anti-parasitic activity. Recently, we
have investigated the behaviour of quinoxalines as reactants for
the one-pot building of complex ring systems through the well
known 1,3-dipolar cycloaddition reactions (1,3-DCR) with nitrili-
mine dipoles, generated in situ from chloroarylhydrazones of type
2.5 By using this approach we successfully realized the one pot syn-
thesis of the tetrahydrobis-1,2,4-triazolo[4,3-a:30,40-c]quinoxaline
derivatives of type 4. All possible biscycloadduct diastereoisomers
(meso form RS, and racemic mixture RR and SS) were obtained,
but the monocycloadduct 3was never isolated6 (Scheme 1).
On the contrary, when the dipolarophile component was non-
symmetric (5 or 7), the reaction route was different leading also
to the formation of the monocycloadducts 6bis together with the
biscycloadducts 6 or 8, this last only as a RR/SS racemic mixture.
However, the presence of the methyl group in position 2 on the
quinoxaline 7 allowed also to isolate, from the reaction mixture,
the spiro-cycloadduct of type 8bis7 (Scheme 2).
With the aim to explore further the inﬂuence of the dipolaro-
phile asymmetry in the 1,3-DCR involving the pyrazine nucleus,
2-phenylpyrrole[2,3-b]pyrazine (9) was chosen as 2p component.
The reaction with chloroarylhydrazones led to the tetrahydropyr-
rolo[2,3-e]bis[1,2,4]triazolo[3,4-c:40,30-a]pyrazines of type 10. It
was also possible to isolate, in good yields, as main component,
the tricyclic monoadduct pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyra-
zine 12 together with the monocycloadduct 138 (Scheme 3).
A broad selection of these polycondensed azines presenting a
wide pattern of substitutions was submitted to In vitro biological
screening9 against a panel of protozoarian agents: Plasmodium falci-
parum (chloroquine sensitive strain GHA), Leishmania infantum, Try-
panosoma brucei and Trypanosoma cruzi. These test organisms were
selected as primary screening model for the parasitic diseases ma-
laria, leishmaniasis, sleeping sickness, and Chagas disease, respec-
tively, so that a wide range of activity can be explored. Some of the
tested compounds resulted active atmicromolar level and,more sig-
niﬁcantly, structurally different compounds showed selectivity for
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different species of microorganisms (Table 1). Only derivatives 4b
and 8d resulted aspeciﬁc, with IC50 in the range 2.1-12.6 lMagainst
all the testedagents. Compound4g resultedactiveandvery selective
against T. brucei at IC50 = 2.06 lMin different condition of solubility,
and against T. cruzi at IC50 <10 lM.
Other two compounds of the series of bis-triazoloquinoxaline
showed selectivity against T. cruzi at IC50 <10 lM. Compound 8a
showed also activity against P. falciparum (IC50 = 11.62 lM).
Bis-triazoloquinoxaline derivatives showed activity also against T.
brucei: in fact compounds 4c, 4g and 8d demonstrated high level
of inhibition capability with IC50 = 2.00 lM. But, whereas 8d was
active on all the four tested parasitic agents (IC50 in the range
2.06–10.08 lM), the only one revealed to be selective against T.
brucei was compound 4c.
Polycondensed azines were generally inactive against Leishama-
nia infantum, but again compound 8d was the only one of the
tested series with IC50 <10 lM. Compound 8b, a bis-triazoloqui-
noxaline derivative, resulted to be the most active and selective
against Plasmodium falciparum (IC50 <1.9 lM), although also com-
pounds 10a and 10b, belonging to the series of bis-triazolopyrrol-
opyrazine, exhibited inhibitory activity, but at higher
concentration.
In parallel with anti-parasitic tests, cytotoxicity on host cells
was also determined, using MRC-5 cells, because these tests repre-
sent a very important criterion for assessing the selectivity of the
observed biological activities. The majority of diazine derivatives
resulted non toxic at studied concentrations, although 4b, 4c, 4e,
4g showed toxicity at concentrations lower than 64 lM. However,
N
N
N
H
Ph
2
N
N N
N
Ar
R
N
N
R
ArNH
Ph
N
N N
N
Ar
R
N
H
Ph
N
H
N N
N
Ar
R
N
H
Ph
N
N N
N
Ar
R
N
H
Ph
9
10 11
1213
H
H
Scheme 3. 1,3-DCR with pyrrolopyrazine ring as dipolarophile.
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considering the Selectivity Index (ratio toxicity/activity) in the case
of T. brucei, the more active compounds compound, 4c, 4g and 8d,
resulted quite safe (SI range 2–32) as well as those, 4g and 8a, 4d,
for which inhibitory capability towards T. cruzi was evidenced (SI
range 6–16). Better selectivity was revealed by compounds active
against P. falciparum, especially in the case of the most active one
8b, which combines selectivity towards the protozoarian agent
with safety (SI value reaching 128).
Once deﬁned the inhibitory activity of these polycondensed dia-
zines, the next step was to try to identify the molecular target re-
lated to each microorganism. Several proteins have been already
identiﬁed as responsible of the metabolism of these parasites,
therefore the research pointed towards new anti-parasitic inhibi-
tors which have to be speciﬁc binders of parasite proteins. For in-
stance, it is known that Plasmodium has a limited ability to
synthesize amino acids, so that it needs to ﬁnd them pre-formed
in the intra-erythrocyte environment, degradating hemoglobin to
get the required amino acids and energy, or it needs to synthesize
nucleic acid by means dihydrofolate reductase (pfDHFR) which, on
the contrary of the mammalian one, also works as timidilate syn-
thase. The same concept can be extended to Trypanosomes and
Leishmanias which, for instance, have to ﬁght the oxidative stress
by means speciﬁc enzyme as trypanothione reductase, the parasite
analogous of the mammalian enzyme glutathione reductase, or use
speciﬁc proteases as well. Therefore we carried out a mixed molec-
ular modeling approach (InducedFit Docking (IFD)/MM-GBSA) in
the attempt to identify the molecular target of our selective
compounds.
We started identifying into the Protein Data Bank (PDB)10 the
3D structures relative to most common, and crucial for the para-
sites metabolism, enzymes: pfDHFR, plasmepsin, dihydroorotate
dehydrogenase (DODH) for Plasmodium; trypanothione reductase
(TR) and DHFR timidilate synthase (tcDHFR-TS), cruzain for Try-
panosoma cruzi; pteridine reductase 1 (PTR1) for Trypanosoma bru-
cei; and trypanothione reductase (TR) for Leishmania. More than
one hundred structures were retrieved, but they were ﬁltered
according to the presence of co-crystallized inhibitors. Moreover
a preliminary docking calculation by means Glide XP11 was carried
out with the aim to identify which protein-inhibitor complex could
be better reproduced. Calculation of crystallized-docked superim-
position root mean square deviation (RMSD) gives an estimation
of the good quality of docking runs, and allows to select the more
suitable complex to be used in further analysis. The lower value of
RMSD for each protein-inhibitor complex guided the selection of
the structure to be used for the IFD analysis of polycondensed dia-
zine compounds; also in the case of the presence of a single pro-
tein-inhibitor complex RMSD values are suitable to select the
structure. A list of the ﬁltered complexes is reported in Table 2.
Thus, IFD calculation on identiﬁed complexes was carried out
ﬁrst. IFD is a mixedMolecular Dynamics/Docking protocol,12 devel-
oped by Schrödinger Inc. (http://www.schrodinger.com/). This ap-
proach combines, in an iterative fashion, the ligand docking
techniques with those for modeling receptor conformational
changes. We used the same calculation settings set in our recent
work.13 IFD calculation were followed by Prime/MM-GBSA for
the estimation of DGbinding. The MM-GBSA approach employs
molecular mechanics, the generalized Born model and the solvent
accessibility method to elicit free energies from structural informa-
tion circumventing the computational complexity of free energy
simulations wherein the net free energy is treated as a sum of a
comprehensive set of individual energy components, each with a
physical basis.14,15
Table 1
In vitro activity against parasitic agents and cytotoxicity on host cells (IC50 in lM)
Compds R Ar Solubility* MRC-5 T. cruzi L. infantum T. brucei P. falciparum-GHA
4a COMe Ph M 64.00 38.14 32.00 64.00 64.00
4b (meso) COMe Ph M 29.63 12.60 32.46 8.06 8.48
4c COPh Ph M
NS
64.00
17.55
64.00 32.46 2.03
2.03
27.66
4d COOMe Ph M 64.00 64.00 64.00 64.00 12.26
4e (meso) COOMe Ph M 33.07 42.47 64.00 34.56 25.58
4f COOEt pCl-C6H4 M 64.00 64.00 64.00 64.00 37.33
4g (meso) COOEt pCl-C6H4 M
NS
48.50
12.44
8.75 32.00 2.06
2.01
18.61
4h H Ph M 64.00 64.00 64.00 64.00 29.76
6 COOMe pCl-C6H4 M 64.00 64.00 64.00 64.00 42.57
6bis COOMe Ph M 64.00 64.00 64.00 64.00 64.00
8a COOMe Ph M
M
64.00 6.22
4.29
64.00 64.00 11.62
8b COOEt pCl-C6H4 M
NS
64.00 64.00 64.00 64.00 0.50
1.90
8c COMe Ph M 64.00 33.71 24.05 32.22 29.23
8d COPh Ph M 64.00 10.08 8.00 2.06 8.23
8bis COOMe pCl-C6H4 M 64.00 64.00 64.00 64.00 64.00
10a COOMe Ph M 64.00 64.00 32.46 64.00 6.87
10b COMe Ph P
NS
64.00 64.00 32.46 64.00 2.15
11.62
10c COOEt pCl-C6H4 M 64.00 40.32 64.00 32.23 26.91
13a Ph Ph P 64.00 64.00 64.00 64.00 64.00
13b COOMe Ph P 64.00 64.00 64.00 64.00 64.00
* M =moderate in 13% DMSO/water; P = poor in 100% DMSO; NS no solubility issue.
Table 2
Filtered PDB complexes and RMSD values (expressed in Å) for the superimposition of
crystallized-docked ligands
LIGAND PDB RMSD
Plasmodium Plasmepsin RS370 1LF2 1.3078
pfDHFR Pyrimethamine 2BL9 0.2973
DODH Genz667348 3O8A 0.2215
T. brucei PTR1 Pemetrexed 2X9G 1.8340
L .infantum TR Antimonium 2W0H 2.4228
T. cruzi TR Spermidine 1BZL 0.8565
tcDHFR-TS Methotrexate 3CL9 0.7310
Cruzain Zya 1AIM 0.6806
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We carried out simulation only on most active compounds (IC50
<10 lM), and DGbinding were also calculated for co-crystallized li-
gands as reference compounds, in order to compare the binding
capability of our polycondensed diazine derivatives with that of
known inhibitors interacting with the proposed target. A ﬁrst con-
sideration can be done for Plasmodium DODH, for T. brucei PTR1
and L. infantum TR: no valuable results were obtained for these tar-
gets. Therefore anti-malarial activity of the studied polycondensed
diazines seems not dependent from inhibition of DODH; nor tri-
panosomal inhibition found for 4b, 4c, 4g can be related to reduc-
tase interaction. Moreover, it is unlikely that the only compound
active against L. infantum (8d) interacts with TR.
Compound 8a and 8d showed a good binding capability both for
Cruzain and tcTR if compared to reference compounds, with
DGbinding up to 6 Kcal/mol more negative than that calculated for
Zya and spermidine, respectively. But, no valuable DGbinding could
be calculated for compound 4g, the other derivative which showed
to be good inhibitor of T. cruzi strains. When docked to Cruzain,
compound 8a forms a H-bond interaction with Gly166 by means
the triazole nitrogen; the benzofused portion of quinoxaline inserts
in the hydrophobic pocket created by Leu67, Ala133, and Leu157,
as shown in Figure 1a. Other hydrophobic interactions stabilize
the binding: the ester methyl interact with Trp26 and Ala156,
respectively, but also the methyl bound to quinoxaline contributes
to the interactions by means Leu67. When we consider tcTR-8a
docking mode (Fig. 1b), no H-bonds formation was evidenced
and the number of hydrophobic interactions is lower than in the
case of Cruzain-8a complex. Therefore although 8a can bind to
both proteins, more stable could be considered the complex with
tcTR.
When docked to Cruzain, compound 8d also forms a H-bond
with Gly166, this time by means the carbonyl oxygen, which in-
volves that the benzofused moiety interacts only with Leu67
(Fig. 2a). One of the phenyl bound to carbonyl strongly interacts
with the hydrophobic pocket created by Trp26, Met68, Ala133,
Leu157, as far as the phenyl bound to triazole nitrogen interacts
with Ala156. When we consider docking of the same compound
8d to tcTR (Fig. 2b), no H-bonds were identiﬁed, but the higher cal-
culated binding capability, with respect to 8a, is due to more tight
hydrophobic interactions which are established with phenyl rings
of substituents (Leu63, Phe367, Cys58, Leu334, Pro336, Val59,
Val54).
In the case of compound 8b, the most active and selective
against P. falciparum (SI = 128) in our series, excellent results were
found only when docking to pfDHFR was considered, with binding
Figure 1. Compound 8a docked to Cruzain (a) and to tcTR (b).
Figure 2. Compound 8d docked to Cruzain (a) and to tcTR (b).
Figure 3. Compound 8b docked to pfDHFR.
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capability comparable to that of the reference compound pyri-
methamine, paralleling thus the results of in vitro screenings
(Fig. 3). The ethyl chain inserts into the hydrophobic pocket cre-
ated by Met54, Phe57, Ile121, and Leu128. The docking mode
was strengthened also by the other hydrophobic interactions of
p-chloro-phenyl rings with Tyr125, for one of them, and Pro122
and Leu45 for the other one, together with the interactions be-
tween the benzofused ring of quinoxaline with Leu45 and Trp47.
In summary, in this work we presented a series of polycon-
densed diazine compounds which revealed interesting in vitro
activity against some parasites, generally joined to low level of tox-
icity. By means in silico studies we tried to identify their molecular
mechanism of action. For some of the more active compounds it
was possible deﬁne the most likely molecular target, so that the
subsequent optimization of these series can be undertaken.
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